AETHLON MEDICAL, INC. (AEMD) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth Win.
32/72
2.2 / 5 stars
All 72 Win/Lose results and 48 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 2 wins, 6 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseAEMD / S&P -62.56% / 15.20% |
No dataAEMD / S&P / 15.00% |
LoseAEMD / S&P -90.75% / 50.40% |
| 2026-Q10/2 |
LoseAEMD / S&P -20.94% / -4.33% |
No dataAEMD / S&P / 11.30% |
LoseAEMD / S&P -27.33% / 27.70% |
| 2025-Q41/2 |
LoseAEMD / S&P -63.07% / 2.65% |
No dataAEMD / S&P / 9.00% |
WinAEMD / S&P 34.76% / 13.40% |
| 2025-Q31/2 |
LoseAEMD / S&P -37.50% / 8.12% |
No dataAEMD / S&P / 4.61% |
WinAEMD / S&P 69.74% / 13.45% |
| 2025-Q21/2 |
LoseAEMD / S&P -58.33% / 10.94% |
No dataAEMD / S&P / 4.83% |
WinAEMD / S&P 163.22% / 10.63% |
| 2025-Q11/2 |
LoseAEMD / S&P -58.14% / -4.27% |
No dataAEMD / S&P / 4.98% |
WinAEMD / S&P 70.72% / 10.57% |
| 2024-Q42/2 |
WinAEMD / S&P 82.98% / 2.41% |
No dataAEMD / S&P / 5.25% |
WinAEMD / S&P 1187.10% / 6.15% |
| 2024-Q31/2 |
LoseAEMD / S&P -6.00% / 5.89% |
No dataAEMD / S&P / 5.89% |
WinAEMD / S&P 1042.03% / 6.11% |
| 2024-Q21/2 |
LoseAEMD / S&P -70.24% / 4.28% |
No dataAEMD / S&P / 5.38% |
WinAEMD / S&P 638.90% / 5.12% |
| 2024-Q11/2 |
LoseAEMD / S&P -23.29% / 10.56% |
No dataAEMD / S&P / 5.71% |
WinAEMD / S&P 805.83% / 5.59% |
| 2023-Q41/2 |
LoseAEMD / S&P -4.78% / 11.69% |
No dataAEMD / S&P / 6.81% |
WinAEMD / S&P 40.91% / 7.78% |
| 2023-Q31/2 |
LoseAEMD / S&P -36.11% / -3.27% |
No dataAEMD / S&P / 7.52% |
WinAEMD / S&P 97.95% / -5.03% |
| 2023-Q21/2 |
LoseAEMD / S&P -5.26% / 8.74% |
No dataAEMD / S&P / 9.50% |
WinAEMD / S&P 646.58% / -8.57% |
| 2023-Q13/3 |
WinAEMD / S&P 35.71% / 7.50% |
WinAEMD / S&P 95.21% / 10.77% |
WinAEMD / S&P 512.86% / -15.69% |
| 2022-Q40/2 |
LoseAEMD / S&P -51.72% / 7.56% |
LoseAEMD / S&P -95.84% / 11.88% |
No dataAEMD / S&P / -17.99% |
| 2022-Q30/2 |
LoseAEMD / S&P -48.21% / -4.88% |
LoseAEMD / S&P -96.72% / 13.47% |
No dataAEMD / S&P / -1.41% |
| 2022-Q20/2 |
LoseAEMD / S&P -23.29% / -16.10% |
LoseAEMD / S&P -79.50% / 13.71% |
No dataAEMD / S&P / 11.04% |
| 2022-Q10/2 |
LoseAEMD / S&P -21.51% / -4.60% |
LoseAEMD / S&P -55.37% / 15.97% |
No dataAEMD / S&P / 42.23% |
| 2021-Q40/2 |
LoseAEMD / S&P -51.81% / 11.03% |
LoseAEMD / S&P -62.09% / 15.00% |
No dataAEMD / S&P / 96.40% |
| 2021-Q31/2 |
LoseAEMD / S&P -21.54% / 0.58% |
WinAEMD / S&P 48.83% / 10.77% |
No dataAEMD / S&P / 69.42% |
| 2021-Q22/2 |
WinAEMD / S&P 142.36% / 8.55% |
WinAEMD / S&P 27.55% / 6.58% |
No dataAEMD / S&P / 51.81% |
| 2021-Q11/2 |
LoseAEMD / S&P -17.81% / 6.17% |
WinAEMD / S&P 1.37% / -1.06% |
No dataAEMD / S&P / 7.39% |
| 2020-Q42/2 |
WinAEMD / S&P 82.96% / 12.15% |
WinAEMD / S&P 58.87% / -3.72% |
No dataAEMD / S&P / -33.42% |
| 2020-Q31/2 |
LoseAEMD / S&P -33.50% / 8.93% |
WinAEMD / S&P 463.81% / -2.04% |
No dataAEMD / S&P / -27.10% |
| 2020-Q22/2 |
WinAEMD / S&P 33.55% / 20.54% |
WinAEMD / S&P 463.81% / -0.46% |
No dataAEMD / S&P / -27.11% |
| 2020-Q12/2 |
WinAEMD / S&P 58.33% / -19.60% |
WinAEMD / S&P 183.15% / 3.47% |
No dataAEMD / S&P / -14.75% |
| 2019-Q41/2 |
LoseAEMD / S&P -72.17% / 9.07% |
WinAEMD / S&P 133.23% / 5.36% |
No dataAEMD / S&P / 2.99% |
| 2019-Q30/2 |
LoseAEMD / S&P -37.84% / 1.70% |
LoseAEMD / S&P -63.24% / 5.02% |
No dataAEMD / S&P / 0.21% |
| 2019-Q20/2 |
LoseAEMD / S&P -61.05% / 4.30% |
LoseAEMD / S&P -63.24% / 6.64% |
No dataAEMD / S&P / 8.65% |
| 2019-Q11/2 |
LoseAEMD / S&P -42.77% / 13.65% |
WinAEMD / S&P 53.47% / 8.12% |
No dataAEMD / S&P / 14.29% |
| 2018-Q42/2 |
WinAEMD / S&P 40.68% / -13.52% |
WinAEMD / S&P 200.00% / 9.05% |
No dataAEMD / S&P / 18.23% |
| 2018-Q30/1 |
LoseAEMD / S&P -7.81% / 7.71% |
No dataAEMD / S&P / 10.21% |
No dataAEMD / S&P / 19.06% |
| 2018-Q21/1 |
WinAEMD / S&P 7.56% / 3.43% |
No dataAEMD / S&P / 9.03% |
No dataAEMD / S&P / 14.46% |
| 2018-Q11/1 |
WinAEMD / S&P 5.31% / -0.76% |
No dataAEMD / S&P / 7.68% |
No dataAEMD / S&P / 12.46% |
| 2017-Q40/1 |
LoseAEMD / S&P -26.62% / 6.64% |
No dataAEMD / S&P / 7.03% |
No dataAEMD / S&P / 13.82% |
| 2017-Q30/1 |
LoseAEMD / S&P -28.04% / 4.48% |
No dataAEMD / S&P / 5.68% |
No dataAEMD / S&P / 17.57% |
| 2017-Q20/1 |
LoseAEMD / S&P -34.56% / 3.09% |
No dataAEMD / S&P / 4.83% |
No dataAEMD / S&P / 17.74% |
| 2017-Q10/1 |
LoseAEMD / S&P -22.14% / 6.07% |
No dataAEMD / S&P / 3.67% |
No dataAEMD / S&P / 13.32% |
| 2016-Q40/1 |
LoseAEMD / S&P -16.33% / 3.82% |
No dataAEMD / S&P / 2.09% |
No dataAEMD / S&P / 7.05% |
| 2016-Q30/1 |
LoseAEMD / S&P -11.93% / 3.85% |
No dataAEMD / S&P / 0.20% |
No dataAEMD / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AEMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -88.40% | 20.78% |
| Annualized return | -88.40% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AEMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.93% | 83.14% |
| Annualized return | -76.41% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AEMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -64.17% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |